TMCnet News
BioCentury & Thomson Reuters to Convene the 20th Future Leaders in the Biotech IndustryREDWOOD CITY, CA and NEW YORK, NY, Apr 03, 2013 (Marketwired via COMTEX) -- BioCentury and Thomson Reuters will convene the 20th Annual Future Leaders in the Biotech Industry in New York City this Friday, April 5th at 8 a.m. at the Millennium Broadway Hotel & Conference Center. The event showcases a full slate of 45 biopharma companies hand-picked on the basis of investor validation, upcoming milestones, unpartnered assets and innovative science, informed by the collective intelligence of BioCentury and Thomson Reuters. Hundreds of life science investment professionals and pharmaceutical business development and licensing executives have pre-registered for the event. Walk-up registration is available at the Millennium Broadway starting at 7:15 a.m. on Friday, April 5th. Public companies at Future Leaders are collectively up 20% this year, easily out-distancing the 16% jump in the BioCentury 100 Index as well as the 11% gain in the Dow Jones Industrial Average and 10% gain in the S&P 500. Over that same period, the aggregate market cap of the Future Leaders public companies has grown by almost $1 billion, from $5.3 billion to $6.2 billion. The Future Leaders Class of 2013 includes 30 public and 15 private companies that have raised $4.3 billion in capital, including $2 billion since the beginning of 2012. The Class of 2013 showcases companies with a solid mix of innovative science and platform assets and ample partnering opportunities. Features for this year's slate include a track of companies nearing critical proof-of-concept data events, fresh IPO stories, public plays nearing commercialization milestones and upcoming Phase III data sets and selected international companies with key value inflection points. Key diseases areas include cancer, infectious diseases, selected neurology and cardiovascular areas and endocrine/metabolic disorders. These Future Leaders have 6 marketed products, 12 programs in Phase III/Registration, 58 programs in Phase II development, 40 programs in Phase I development and at least 75 programs in preclinical development. 125 programs are currently unpartnered. "Biotech's bull run on Wall Street is not done," said BioCentury Publisher Eric Pierce. "The Future Leaders Class of 2013 is aiming to show how they can create more value for investors going forward." Money managers attending the conference control over $400 billion in equity assets, nearly $100 billion in healthcare assets, and almost $15 billion in biotech assets. The 2013 Presenting Companies Presenting companies were screened using Thomson Reuters and BioCentury industry analysis and proprietary databases, including BioCentury's BCIQ online business intelligence platform. The result is an independently selected mix of companies with proven fundraising capacity, the prospect for key partnerships and proximity to potentially transformational milestones. (Stock symbols shown for publicly traded companies; listed on NASDAQ unless noted). Acceleron Pharma Inc. Acetylon Pharmaceuticals Inc. Adocia S.A. (ADOC) Alexza Pharmaceuticals Inc. (ALXA) Catabasis Pharmaceuticals Inc. Celladon Corp. Curis Inc. (CRIS) Cytokinetics Inc. (CYTK) Cytori Therapeutics Inc. (CYTX; XMPA) Cytos Biotechnology AG (CYTN) Dicerna Pharmaceuticals Inc. Endocyte Inc. (ECYT) Flexion Therapeutics Inc. Forma Therapeutics Holdings LLC Furiex Pharmaceuticals Inc. (FURX) Galena Biopharma Inc. (GALE) GlobeImmune Inc. Heptares Therapeutics Ltd. Horizon Pharma Inc. (HZNP) ImmunoCellular Therapeutics Ltd. (IMUC) Inovio Pharmaceuticals (INO) Insmed Inc. (INSM) KaloBios Pharmaceuticals Inc. (KBIO) Nanobiotix S.A. (NANO) Navidea Biopharmaceuticals Inc. (NAVB) Nuron Biotech Inc. Omeros Corp. (OMER) OncoGenex Pharmaceuticals Inc. (OGXI) Onconova Therapeutics Inc. Oncothyreon Inc. (ONTY) Regulus Therapeutics Inc. (RGLS) Relypsa Inc. Repros Therapeutics Inc. (RPRX) Resverlogix Corp. (RVX) Sorbent Therapeutics Inc. Sucampo Pharmaceuticals Inc. (SCMP) SymBio Pharmaceuticals Ltd. (4582) TESARO Inc. (TSRO) Threshold Pharmaceuticals Inc. (THLD) Trimel Pharmaceuticals Corp. (TRL) Trius Therapeutics Inc. (TSRX) Ultragenyx Pharmaceutical Inc. uniQure B.V. Vanda Pharmaceuticals Inc. (VNDA) Verastem Inc. (VSTM) See the Presenting Company schedule and additional program highlights at http://www.biocentury.com/data/newscenter2/conferences/conferencesfiles/FL13schedule.pdf. Top Sponsors Demonstrate Long-Term Commitment to Industry The prestigious group of 2013 sponsors is anchored by Gold Sponsors Brinson Patrick Securities, Maxim Group and WBB Securities; Silver Sponsors AstraZeneca plc and Bloom Burton & Co.; and luncheon sponsor Flanders Investment and Trade. This premier Wall Street event is one of two annual investor conferences organized by BioCentury and Thomson Reuters. The next conference, NewsMakers in the Biotech Industry, will take place in New York City on September 27, 2013, at the Millennium Broadway Hotel & Conference Center. About BioCentury Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury(R), the Bernstein Report on BioBusiness; its SciBX: Science-Business eXchange(TM) translational science partnership with Nature Publishing Group; and its BioCentury Extra(TM) online daily newspaper. These timely journals are backed by BCIQ: BioCentury Online Intelligence(TM), an online business intelligence resource. BioCentury also produces its BioCentury This Week biotech public affairs television program in partnership with the Gannett-owned WUSA9 CBS affiliate in Washington, D.C. The program is aired in Washington each Sunday as part of the WUSA9 Sunday Morning Power Block, on Public Broadcasting System member stations in selected markets and distributed globally online at www.biocenturytv.com. For more information, visit www.biocentury.com and www.biocenturytv.com. About Corporate Services The Corporate Services business unit of Thomson Reuters provides insight, analytics and communications solutions to Investor Relations, Public Relations, Marketing and Internal Communications professionals at thousands of companies worldwide. Our clients rely on our desktop, mobile, advisory and multimedia solutions to: monitor markets and peers, prioritize their outreach, reach and engage target audiences and measure the impact of their programs. About Thomson Reuters Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to http://thomsonreuters.com. SOURCE: BioCentury Publications, Inc. |